慢性HBV感染不同临床阶段患者外周血T细胞免疫状态的研究
发布时间：2021-10-20 15:19
目的:探讨慢性HBV感染（CHI）不同临床阶段患者外周血T细胞状态,为CHI临床分期和防治提供科学依据。方法:本研究收录CHI患者,按照患者临床症状将其划分为免疫耐受（IT）、免疫活跃（IA）、免疫控制（IC）、再活化组（RA）,健康志愿者（HD）为对照组。分离外周血单个核细胞（PBMC）,使用多色流式细胞术分析患者外周血CD4+T细胞、CD8+T细胞亚群频率和CD8+T细胞表面PD-1的表达量。结果:与HD相比,CHI组T细胞及亚群变化无显著差异;RA组CD3+T细胞百分比显著下降。对于CD8+T细胞亚型,IC和RA组初始CD8+T细胞（Na?ve T cell,Tn）频率下降;IT组效应记忆CD8+T细胞（Tem）频率降低;而IC组效应CD8+T细胞（Te）频率显著增高（P<0.05）。相较于高HBV DNA载量组（IT）,低HBV DNA载量组（IC和RA）Tn频率降低,Te频率增高（P<0.0...
【文章来源】：中国免疫学杂志. 2020,36(12)北大核心CSCD
【文章页数】：5 页
【部分图文】：
外周血T细胞亚型分析
与HD相比,CHI中各组PD-1+CD8+T细胞百分比均显著增高(P<0.05);CHI中IT、IA、IC、RA组,两两之间比较,IA、IC组PD-1+CD8+T细胞百分比升高最为明显,其次是RA组,与HD相比,有统计学意义(P<0.05)(图3B)。图3 CHI不同临床阶段Treg频率及PD-1+CD8+T细胞百分比分析
图2 CD8+T细胞亚型与HBV DNA载量的关系表1 CHI不同临床阶段患者外周血T细胞亚群分析Tab.1 Analysis of T cell subsets from PBMCs in patients with chronic HBV at different clinical stages T cell subsets Healthy donor HD Clinical stages of chronic HBV infection IT IA IC RA CD3+T(%) 69.13(53.68-79.80) 66.9(60.25-73.67) 61.35(52.13-67.10) 70.33(64.73-76.38) 52.22(34.33-62.23) CD4+T(%) 51.34(46.05-54.58) 50.12(40.18-73.63) 48.16(33.33-69.10) 54.73(43.50-75.03) 53.16(43.80-62) CD8+T(%) 35.9(29.9-40.60) 35.17(18.95-47.38) 42.37(27.25-62.43) 33.21(18.15-46.75) 38.19(30.30-52.45) CD4+/CD8+ 1.44(1.21-1.69) 1.61(0.85-3.89) 1.34(0.53-2.54) 1.93(0.96-3.83) 1.46(0.84-2.05) CD4+CD25+CD127-Treg(%) 1.96(1.41-2.60) 2.65(2.55-2.72) 4.00(3.35-4.55) 2.24(1.42-3.20) 3.34(2.34-4.76) CD4+T cell subsets Tn(%) 35.84(21.80-56.10) 28.62(20.7-47.90) 34.80(19.80-48) 27.73(10.40-41.10) 22.81(5.64-38.60) Tcm(%) 40.41(31.50-52.50) 51.32(33.20-70.30) 47.76(25.20-61.30) 45.32(32.10-63.70) 49.9(44.50-61.40) Tem(%) 22.68(11.50-34) 16.57(9.53-25.40) 15.82(11.40-23.30) 24.91(12.70-53.50) 24.72(11.60-40.90) Te(%) 1.07(0.37-2.20) 3.49(0.18-16.30) 1.61(0.51-4.19) 2.02(0.20-3.80) 2.54(0.41-6.65) CD8+T cell subsets Tn(%) 39.27(26.70-56.50) 41.19(16.40-62.40) 40.86(18.40-62.70) 27.02(17.25-42.40) 24.81(9.76-37.40) Tcm(%) 5.80(1.24-12.90) 9.62(3.21-25.00) 5.84(3.97-7.61) 8.03(4.37-10.80) 9.78(3.86-18.10) Tem(%) 28.01(13.00-38.70) 16.79(7.04-31.70) 22.8(11.90-25.10) 20.55(8.01-38.45) 20.36(8.95-34.60) Te(%) 26.89(10.90-43.80) 32.4(17.70-59.80) 33.93(26.80-47.70) 44.39(36.10-56.10) 37.40(28.70-47.60) PD-1+CD8+(%) 14.32(8.36-18.88) 18.94(12.20-26.74) 25.48(23.29-28.45) 24.47(19.26-28.92) 24.29(13.26-36.70)
【参考文献】：
期刊论文
[1]慢性乙型肝炎防治指南（2019年版）[J]. 王贵强,王福生,庄辉,李太生,郑素军,赵鸿,段钟平,侯金林,贾继东,徐小元,崔富强,魏来. 中华实验和临床感染病杂志(电子版). 2019(06)
[2]Immune response pattern varies with the natural history of chronic hepatitis B[J]. Wen-Tao Wang,Xue-Qi Zhao,Gui-Ping Li,Yi-Zhi Chen,Lin Wang,Mei-Fang Han,Wei-Na Li,Tao Chen,Guang Chen,Dong Xu,Qin Ning,Xi-Ping Zhao. World Journal of Gastroenterology. 2019(16)
[3]Peripheral T-lymphocyte subpopulations in different clinical stages of chronic HBV infection correlate with HBV load[J]. Hutcha Sriplung,Alan Geater,Virasakdi Chongsuvivatwong,Teerha Piratvisuth,Edward McNeil. World Journal of Gastroenterology. 2009(27)
本文编号：3447141
【文章来源】：中国免疫学杂志. 2020,36(12)北大核心CSCD
【文章页数】：5 页
【部分图文】：
外周血T细胞亚型分析
与HD相比,CHI中各组PD-1+CD8+T细胞百分比均显著增高(P<0.05);CHI中IT、IA、IC、RA组,两两之间比较,IA、IC组PD-1+CD8+T细胞百分比升高最为明显,其次是RA组,与HD相比,有统计学意义(P<0.05)(图3B)。图3 CHI不同临床阶段Treg频率及PD-1+CD8+T细胞百分比分析
图2 CD8+T细胞亚型与HBV DNA载量的关系表1 CHI不同临床阶段患者外周血T细胞亚群分析Tab.1 Analysis of T cell subsets from PBMCs in patients with chronic HBV at different clinical stages T cell subsets Healthy donor HD Clinical stages of chronic HBV infection IT IA IC RA CD3+T(%) 69.13(53.68-79.80) 66.9(60.25-73.67) 61.35(52.13-67.10) 70.33(64.73-76.38) 52.22(34.33-62.23) CD4+T(%) 51.34(46.05-54.58) 50.12(40.18-73.63) 48.16(33.33-69.10) 54.73(43.50-75.03) 53.16(43.80-62) CD8+T(%) 35.9(29.9-40.60) 35.17(18.95-47.38) 42.37(27.25-62.43) 33.21(18.15-46.75) 38.19(30.30-52.45) CD4+/CD8+ 1.44(1.21-1.69) 1.61(0.85-3.89) 1.34(0.53-2.54) 1.93(0.96-3.83) 1.46(0.84-2.05) CD4+CD25+CD127-Treg(%) 1.96(1.41-2.60) 2.65(2.55-2.72) 4.00(3.35-4.55) 2.24(1.42-3.20) 3.34(2.34-4.76) CD4+T cell subsets Tn(%) 35.84(21.80-56.10) 28.62(20.7-47.90) 34.80(19.80-48) 27.73(10.40-41.10) 22.81(5.64-38.60) Tcm(%) 40.41(31.50-52.50) 51.32(33.20-70.30) 47.76(25.20-61.30) 45.32(32.10-63.70) 49.9(44.50-61.40) Tem(%) 22.68(11.50-34) 16.57(9.53-25.40) 15.82(11.40-23.30) 24.91(12.70-53.50) 24.72(11.60-40.90) Te(%) 1.07(0.37-2.20) 3.49(0.18-16.30) 1.61(0.51-4.19) 2.02(0.20-3.80) 2.54(0.41-6.65) CD8+T cell subsets Tn(%) 39.27(26.70-56.50) 41.19(16.40-62.40) 40.86(18.40-62.70) 27.02(17.25-42.40) 24.81(9.76-37.40) Tcm(%) 5.80(1.24-12.90) 9.62(3.21-25.00) 5.84(3.97-7.61) 8.03(4.37-10.80) 9.78(3.86-18.10) Tem(%) 28.01(13.00-38.70) 16.79(7.04-31.70) 22.8(11.90-25.10) 20.55(8.01-38.45) 20.36(8.95-34.60) Te(%) 26.89(10.90-43.80) 32.4(17.70-59.80) 33.93(26.80-47.70) 44.39(36.10-56.10) 37.40(28.70-47.60) PD-1+CD8+(%) 14.32(8.36-18.88) 18.94(12.20-26.74) 25.48(23.29-28.45) 24.47(19.26-28.92) 24.29(13.26-36.70)
【参考文献】：
期刊论文
[1]慢性乙型肝炎防治指南（2019年版）[J]. 王贵强,王福生,庄辉,李太生,郑素军,赵鸿,段钟平,侯金林,贾继东,徐小元,崔富强,魏来. 中华实验和临床感染病杂志(电子版). 2019(06)
[2]Immune response pattern varies with the natural history of chronic hepatitis B[J]. Wen-Tao Wang,Xue-Qi Zhao,Gui-Ping Li,Yi-Zhi Chen,Lin Wang,Mei-Fang Han,Wei-Na Li,Tao Chen,Guang Chen,Dong Xu,Qin Ning,Xi-Ping Zhao. World Journal of Gastroenterology. 2019(16)
[3]Peripheral T-lymphocyte subpopulations in different clinical stages of chronic HBV infection correlate with HBV load[J]. Hutcha Sriplung,Alan Geater,Virasakdi Chongsuvivatwong,Teerha Piratvisuth,Edward McNeil. World Journal of Gastroenterology. 2009(27)
本文编号：3447141
本文链接：https://www.wllwen.com/yixuelunwen/chuanranbingxuelunwen/3447141.html
最近更新
教材专著
